Neuronetics (STIM) Stock Price, News & Analysis

Company Overview

Neuronetics, Inc. is a medical technology company that develops and commercializes noninvasive treatments for certain mental health conditions. Its flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain.

NeuroStar is FDA-cleared for treating major depressive disorder in adults who have not achieved satisfactory improvement with antidepressant medication. The company also provides treatment-related services and support for clinicians and patients.

Based in Malvern, Pennsylvania, Neuronetics serves the U.S. market and reaches some international markets through distribution partners. Its business focuses on making neurostimulation therapy available through healthcare providers and treatment centers.

Key Stats

• Today's Range: $1.20 to $1.44
• 50-Day Range: $1.39 to $3.04
• 52-Week Range: $0.80 to $3.44
• Volume: 16.25 million shs
• Average Volume: 2.08 million shs
• Market Capitalization: $108.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

Neuronetics Stock Analysis - MarketRank™

Neuronetics scored higher than 73% of companies evaluated by MarketBeat, and ranked 186th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Neuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Neuronetics has a consensus price target of $5.00, representing about 259.7% upside from its current price of $1.39.

Amount of Analyst Coverage

Neuronetics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neuronetics are expected to grow in the coming year, from ($0.30) to ($0.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neuronetics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neuronetics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neuronetics has a P/B Ratio of 4.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.35% of the float of Neuronetics has been sold short.

Short Interest Ratio / Days to Cover

Neuronetics has a short interest ratio ("days to cover") of 9.89.

Change versus previous month

Short interest in Neuronetics has recently decreased by 7.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuronetics does not currently pay a dividend.

Dividend Growth

Neuronetics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.19

News Sentiment

Neuronetics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Neuronetics this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for STIM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added Neuronetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Neuronetics insiders have sold 3,618.37% more of their company's stock than they have bought. Specifically, they have bought $120,460.00 in company stock and sold $4,479,146.00 in company stock.

Percentage Held by Insiders

8.40% of the stock of Neuronetics is held by insiders.

Percentage Held by Institutions

53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:STIM
• CIK: 1227636
• Web: www.neurostar.com
• Phone: (610) 640-4202
• Fax: 610-640-4206
• Employees: 658
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Neuronetics: $5.00
• High Price Target: $6.00
• Low Price Target: $3.00
• Potential Upside/Downside: +259.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39 million
• Net Margins: -14.45%
• Pretax Margin: -14.40%
• Return on Equity: -102.23%
• Return on Assets: -16.83%

Debt

• Debt-to-Equity Ratio: 2.76
• Current Ratio: 2.01
• Quick Ratio: 1.82

Sales & Book Value

• Annual Sales: $149.16 million
• Price / Sales: 0.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 4.79

Miscellaneous

• Outstanding Shares: 77,730,000
• Free Float: 71,199,000
• Market Cap: $108.04 million
• Optionable: Optionable
• Beta: 1.36